Navigation Links
Week in Review in the Health Outcomes and Pharma Pricing Field from HealthEconomics.Com
Date:2/15/2013

Ponte Vedra Beach, Florida (PRWEB) February 15, 2013

The top news story available on HealthEconomics.Com explored results of a study by the European Consortium in Healthcare Outcomes (ECHOUTCOME) claiming that the QALY (quality-adjusted life years) has failed as a common metric for assessing cost-benefit of drug therapies. The findings have set off a controversial debate on the continued use of the QALY as a measure for deciding whether or not a drug will be reimbursed by payers or health systems. The QALY is used by NICE (the National Institute for Health and Clinical Excellence) for coverage decisions by the National Health Service in the United Kingdom, as well as by Canada and Australia. Generally if a treatment costs more than £20,000-30,000 per QALY, it would not be recommended as cost-effective by NICE.

The study findings caused a backlash of protests by UK-based experts, defending the current system and NICE called the study "limited". More details on the QALY debate can be found on HealthEconomics.Com News.

Another popular news story related to the Pharmacy Benefit Management (PBM) sector. Costco, the largest warehouse club chain in the United States, has entered into the PBM marketplace with the intent to offer services to small and medium-sized companies located near their warehouse stores. Currently, Express Scripts Holding and CVS Caremark dominate the PBM business. PBMs play a significant role in drug coverage decisions and can dramatically impact the success or failure of a pharmaceutical drug product’s success in the marketplace. For more on the impact of Costco on the PBM marketplace, visit the

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Up to the Challenge: Careers in Science in the Midst of Drastic Change, According to Wysebridge Patent Bar Review
2. Sigma-Aldrich Corporation Will Hold Its Annual Business Review March 21, 2013
3. University of Colorado Cancer Center Review Shows Long-term Side-effects of New, Targeted Therapies in Pediatric Cancer Patients
4. Wysebridge Patent Bar Review Discusses Major Changes To The Patent Bar Exam
5. New EMR Comparison Website Launches Crowdsourcing Electronic Medical Record Software Reviews and Comparisons
6. Independent Marketing Automation Software Expert gives Positive review on MindMatrix's platform, AMP
7. Global Metabolomics Market Reviewed & Forecast in New In-Demand Report Available at MarketPublishers.com
8. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
9. Wysebridge Patent Bar Review Announces the Launch of News Blog
10. Review Module Headlines BSI 8.6 Release for Enterprise Biobank Software
11. The 2013 CES: Patents, Legislation Reform, and the Growing Market for Patent Attorneys and Agents Reviewed by Wysebridge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 ... that uses next generation sequencing technology to empower cancer ... Storrer as chief executive officer. In his expanded ... responsible for all strategy, business expansion and worldwide operations ... served as Strand,s chairman and CEO since its founding ...
(Date:7/1/2015)... 2015  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced that the company will ... 5:45 p.m. EDT following its presentation of RVT-101 ... 2015 (AAIC). The event will ... Lawrence Friedhoff , Chief Development Officer, will ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business ... to lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s ... cash prizes of US$15,000 and a period of expert mentorship from a senior industry ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... DIEGO , March 16  Neurocrine Biosciences, Inc. (Nasdaq: ... recently completed public offering of common stock has exercised in ... common stock to cover over-allotments.  The sale of the additional ... into account the sale of the additional shares at a ...
... Shire plc (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice Letter,from Teva Pharmaceuticals USA, Inc. ("Teva") advising of ... release tablets,INTUNIV(TM). , ... , ... ...
... LONDON, ON , March 16 /PRNewswire/ ... protein therapeutic, demonstrated positive results in a pivotal proof ... model for arthritis. VT-346 achieved a statistically significant, dose ... prevented deterioration due to disease in terms of weight ...
Cached Biology Technology:Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering 2Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 2Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 3Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 4
(Date:6/26/2015)... June 26, 2015 ATL Technology, LLC, a top ... specialties in single use solutions, headquartered in Springville, ... (a California corporation with locations in ... San Jose, Costa Rica ). This acquisition ... with ATL Technology,s existing facility in ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Oslo, April 7, 2010: OptiNose, a leader in ... publication in Cephalalgia of results from its ... of its novel, intranasal drug/device product for the treatment ... and 20mg doses administered intranasally using OptiNose,s bi-directional delivery ...
... to exercise, help may be on the way. That,s ... as exercise, promotes new bone growth. This opens the ... into thinking they are getting a workout. The research ... FASEB Journal ( http://www.fasebj.org ). This ...
... Calif.) African-American women have poorer survival rates ... whether they receive radiation therapy following lumpectomy or ... Martinez, assistant professor of surgery at UC Davis ... women with advanced breast cancer are less likely ...
Cached Biology News:OptiNose's novel intranasal sumatriptan product highly effective in treating migraines 2For osteoporosis patients, exercise pill one step closer to reality 2Disparities persist in outcomes for African-American women with advanced breast cancer 2
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... has been designed and created in order ... friendly genotyping analysis tool. We incorporated the ... into the software. Their main requirements were ... low acquisition cost. GeneMarker can perform ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
... 3D structure visualization, phylogenetic tree building, sequence ... single application. Retrieve ... and filter them in real-time Organize ... searching, filtering and sorting Provides up-to-date ...
Biology Products: